502 related articles for article (PubMed ID: 23710803)
1. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
2. Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.
Shahbazi M; Zahedifard F; Saljoughian N; Doroud D; Jamshidi S; Mahdavi N; Shirian S; Daneshbod Y; Hamid Zarkesh-Esfahani S; Papadopoulou B; Rafati S
Vet Parasitol; 2015 Sep; 212(3-4):130-9. PubMed ID: 26255093
[TBL] [Abstract][Full Text] [Related]
3. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.
Saljoughian N; Taheri T; Zahedifard F; Taslimi Y; Doustdari F; Bolhassani A; Doroud D; Azizi H; Heidari K; Vasei M; Namvar Asl N; Papadopoulou B; Rafati S
PLoS Negl Trop Dis; 2013; 7(4):e2174. PubMed ID: 23638195
[TBL] [Abstract][Full Text] [Related]
4. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
Rafati S; Zahedifard F; Nazgouee F
Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
[TBL] [Abstract][Full Text] [Related]
9. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
[TBL] [Abstract][Full Text] [Related]
10. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
Carson C; Antoniou M; Ruiz-Argüello MB; Alcami A; Christodoulou V; Messaritakis I; Blackwell JM; Courtenay O
Vaccine; 2009 Feb; 27(7):1080-6. PubMed ID: 19095029
[TBL] [Abstract][Full Text] [Related]
11. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
Pirdel L; Farajnia S
Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis Identifies Immune Markers Related to Visceral Leishmaniasis Establishment in the Experimental Model of BALB/c Mice.
Agallou M; Athanasiou E; Kammona O; Tastsoglou S; Hatzigeorgiou AG; Kiparissides C; Karagouni E
Front Immunol; 2019; 10():2749. PubMed ID: 31849951
[TBL] [Abstract][Full Text] [Related]
13. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
[TBL] [Abstract][Full Text] [Related]
14. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
15. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
16. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
17. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
[TBL] [Abstract][Full Text] [Related]
18. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
19. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
Sharma A; Madhubala R
J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
